AbbVie (ABBV) announced plans to launch ELAHERE in the U.K. at a list price equal to the U.S., reflecting the advanced innovation and value of the treatment for adult patients with folate receptor-alpha positive, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens. ELAHERE is the first-and-only approved FRalpha-directed antibody drug conjugate medicine.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Video: Drugmakers, Paccar, Wayfair reacting to Trump tariff threats
- AbbVie submits NDA to FDA for tavapadon for treatment of Parkinson’s disease
- AbbVie’s Promising Phase 1 Study on ABBV-CLS-579: A Potential Game-Changer in Cancer Treatment
- Genmab upgraded to Buy at Guggenheim on royalty revenue upside potential
- Kroger, Merck, Workday, AbbVie, Eli Lilly: Trending by Analysts